Champions Oncology (NASDAQ:CSBR – Get Free Report) and Harrow (NASDAQ:HROW – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.
Valuation and Earnings
This table compares Champions Oncology and Harrow”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Champions Oncology | $56.94 million | 1.43 | $4.70 million | ($0.16) | -36.69 |
| Harrow | $272.30 million | 4.71 | -$5.14 million | ($0.41) | -83.98 |
Insider and Institutional Ownership
41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 72.8% of Harrow shares are held by institutional investors. 47.0% of Champions Oncology shares are held by company insiders. Comparatively, 12.8% of Harrow shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Champions Oncology and Harrow’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Champions Oncology | -3.94% | -57.31% | -7.51% |
| Harrow | -5.57% | 19.59% | 2.26% |
Risk & Volatility
Champions Oncology has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.34, suggesting that its share price is 66% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Champions Oncology and Harrow, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
| Harrow | 1 | 2 | 8 | 0 | 2.64 |
Harrow has a consensus target price of $69.43, suggesting a potential upside of 101.65%. Given Harrow’s stronger consensus rating and higher probable upside, analysts clearly believe Harrow is more favorable than Champions Oncology.
Summary
Harrow beats Champions Oncology on 8 of the 14 factors compared between the two stocks.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
About Harrow
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
